Published in Oncoimmunology on June 27, 2016
A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | NCT02009449
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J (1991) 5.30
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med (2002) 3.97
TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant (2004) 3.15
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell (2011) 2.57
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 2.23
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 2.21
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol (1998) 2.05
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol (2011) 1.89
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 1.72
A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol (1999) 1.70
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol (2001) 1.51
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med (1995) 1.42
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol (2000) 1.30
Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med (1996) 1.29
IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res (2012) 1.27
In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax (2006) 1.24
Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood (2001) 1.21
Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood (2009) 1.21
Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol (1996) 1.17
A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J (2000) 1.16
The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression. Eur J Immunol (2009) 1.02
Interleukin 10 inhibits transforming growth factor-beta (TGF-beta) synthesis required for osteogenic commitment of mouse bone marrow cells. J Cell Biol (1994) 0.99
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol (2013) 0.99
Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes (2007) 0.96
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol (1999) 0.95
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PLoS One (2013) 0.94
Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun (2002) 0.92
Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice. Infect Immun (2001) 0.88
Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep. J Neuroimmunol (1995) 0.88
Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother (2000) 0.83
The Potentiation of IFN-γ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells. J Interferon Cytokine Res (2015) 0.82
Interleukin-10 gene transfer activates interferon-gamma and the interferon-gamma-inducible genes Gbp-1/Mag-1 and Mig-1 in mammary tumors. Int J Cancer (1999) 0.79